Genomic Biomarkers Market to Observe Utmost CAGR of 17.5% by 2030, Size, Share, Demand, Key Drivers, Development Trends and Competitive Outlook

Published June 12, 2023

Data Bridge Market Research analyses that the genomic biomarkers market, which is USD 7.59 billion in 2022, is expected to reach USD 27.59 billion by 2030, at a CAGR of 17.5% from 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Genomic Biomarkers Market research report is an ideal guide to attain an information or key data about market, emerging trends, product usage, motivating factors for customers, competitor strategies, brand positioning, customer preferences, and customer behavior. By maintaining quality and transparency strictly, research studies are carried out which offers an outstanding market research report for niche. This global business document is a wide-ranging and object-oriented which is framed after the combination of an admirable industry experience, talent solutions, industry insight and most modern tools and technology. Global Genomic Biomarkers Market report describes the categorization by companies, region, type and end-use industry.

Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @

By 2040, there will be 27.5 million more cancer cases worldwide, according to the International Agency for Research on Cancer (IRAC). The causes of the increasing capacity include smoking, leading an unhealthy lifestyle, and not getting enough exercise. The burden is anticipated to increase beyond IRAC’s prediction, offering more opportunities for specialized treatments. Biopharmaceutical companies are likely to prioritize the expansion of their oncology product lines, which is expected to boost this market’s growth during the forecast period.

Genomic biomarkers are DNA and RNA traits used as diagnostic indicators, disease characterization, and therapy selection tools. The body’s response to treatment as well as pathological and physiological processes, are all represented by genomic biomarkers. Testing for genomic biomarkers can find molecular changes in a single gene, a group of genes, or a whole genome. A relationship between a genetic biomarker and the likelihood of developing a disease may or may not have strong supporting data. Functional laboratory evaluations and genetic epidemiology evidence are two variables that contribute to the clinical validity and usability of genomic biomarkers.


  • The inability to establish an adequate predictive value for the diagnosis of colon cancer will hinder the market growth

A few issues with the use and analysis of genetic biomarkers are anticipated to limit market expansion during the forecast period. According to an article released by the Intestinal Journal in November 2019, genomic biomarkers, such as miRNA found in stool samples, cannot be used as a stand-alone diagnostic tool for the detection of colon cancer.

This genomic biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the genomic biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In 2020, Clinical Genomics Delivery in everyday healthcare was completed under Color Genomics’ U.S. program, the company announced in collaboration with NorthShore University Health System. Also, the business supported Sanford’s Imagenetics genomes program, which will improve clinical judgment. This project is also to blame for the region’s widespread use of genetic biomarkers.
  • In 2020, Gilead Sciences, Inc. and Second Genome announced their four-year strategic partnership to find new potential targets and therapeutic candidates for treating IBD and identify biomarkers linked to clinical response (inflammatory bowel disease).

Some of the major players operating in the genomic biomarkers market are:

  • Thermo Fisher Scientific (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Myriad Genetics, Inc (U.S.)
  • Eurofins Scientific (Luxembourg)
  • QIAGEN (Germany)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • MedGenome (India)
  • Almac Group (U.K.)
  • Sema4 (U.S.)
  • Creative Diagnostics (U.S.)
  • Quanterix (U.S.)

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@

What benefits does the DBMR study is going to provide?

  • Latest industry influencing trends and development scenario
  • Open up New Markets
  • To Seize powerful market opportunities
  • Key decision in planning and to further expand market share
  • Identify Key Business Segments, Market proposition & Gap Analysis
  • Assisting in allocating marketing investments

Global Genomic Biomarkers Market Scope


  • Predictive Biomarkers
  • Prognostic Biomarkers

Disease Indication

  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Renal Disorders
  • Others


  • Analytical Validation
  • Clinical Validation
  • Clinical Utility

End- User

  • Diagnostic
  • Research Laboratories
  • Hospitals
  • Others

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the Genomic Biomarkers Market
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Browse the complete table of contents at –

Genomic Biomarkers Market Regional Analysis/Insights

The genomic biomarkers market is analysed and market size insights and trends are provided by country, type, disease indication, validation, and end-user as referenced above.

The countries covered in the genomic biomarkers market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the genomic biomarkers market because of the rise in genetic biomarkers for early disease diagnosis. For instance, Color Genomics, in partnership with North Shore University Health System, declared in January 2020 that the U.S. program’s adoption of clinical genetics in routine healthcare had been completed.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030, owing to the expansion of healthcare infrastructure initiatives in the Asian economy and the abundance of extremely cutting-edge research facilities in developing countries such as China, India, and Japan. For instance, The Genome Asia 100K Project sequencing (WGS) project makes genetic discoveries possible throughout the Asian economy.

Top DBMR Healthcare Reports:        

Global Genomics Market – Industry Trends and Forecast to 2030

Consumer Genomics Market – Industry Trends and Forecast to 2028

Function Driven Metagenomics Market – Industry Trends and Forecast to 2028

Sequencing Driven Metagenomics Market – Industry Trends and Forecast to 2028

Single Cell Genomics and Proteomics Market – Industry Trends and Forecast to 2030

Genomic Tests Market – Industry Trends and Forecast to 2028

Nutrigenomics Market – Industry Trends and Forecast to 2028

Metagenomics Market – Industry Trends and Forecast to 2028

 Nutrigenomics Testing Market – Industry Trends and Forecast to 2029

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475


CDN Newswire